BACKGROUND:

patients with persistent fever and neutropenia often receive empirical therapy with conventional or liposomal amphotericin B for the prevention and early treatment of invasive fungal infections. Caspofungin, a member of the new echinocandin class of compounds, may be an effective alternative that is better tolerated than amphotericin B.

METHODS:

In this randomized, double-blind, multinational trial, we assessed the efficacy and safety of caspofungin as compared with liposomal amphotericin B as empirical antifungal therapy. At study entry, patients were stratified according to risk and according to whether they had previously received antifungal prophylaxis. A successful outcome was defined as the fulfillment of all components of a five-part composite end point.

RESULTS:

Efficacy was evaluated in 1095 patients (556 receiving caspofungin and 539 receiving liposomal amphotericin B). After adjustment for strata, the overall success rates were 33.9 percent for caspofungin and 33.7 percent for liposomal amphotericin B (95.2 percent confidence interval for the difference, -5.6 to 6.0 percent), fulfilling statistical criteria for the noninferiority of caspofungin. Among patients with baseline fungal infections, a higher proportion of those treated with caspofungin had a successful outcome (51.9 percent vs. 25.9 percent, P=0.04). The proportion of patients who survived at least seven days after therapy was greater in the caspofungin group (92.6 percent vs. 89.2 percent, P=0.05). Premature study discontinuation occurred less often in the caspofungin group than in the amphotericin B group (10.3 percent vs. 14.5 percent, P=0.03). The rates of breakthrough fungal infections and resolution of fever during neutropenia were similar in the two groups. Fewer patients who received caspofungin sustained a nephrotoxic effect (2.6 percent vs. 11.5 percent, P<0.001), an infusion-related event (35.1 percent vs. 51.6 percent, P<0.001), or a drug-related adverse event or discontinued therapy because of drug-related adverse events.

CONCLUSIONS:

Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.

Copyright 2004 Massachusetts Medical Society

Related Articles
Review Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Drugs. 2009
Review Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD, Lyseng-Williamson KA, Scott LJ. Drugs. 2009; 69(3):361-92.
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
N Engl J Med. 1999
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, et al. N Engl J Med. 1999 Mar 11; 340(10):764-71.
An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
J Med Microbiol. 2006
An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M, Frampton C, Joseph J, Alizadeh H, Kristensen J, Hauggaard A, Shammas F. J Med Microbiol. 2006 Oct; 55(Pt 10):1357-65.
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
N Engl J Med. 2002
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, et al. N Engl J Med. 2002 Jan 24; 346(4):225-34.
Review Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Drugs. 2003
Review Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G, Figgitt D. Drugs. 2003; 63(20):2235-63.
Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia.
Case Rep Transplant. 2012
Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia.
Döring M, Zierl A, Mezger M, Lang P, Handgretinger R, Müller I. Case Rep Transplant. 2012; 2012:672923. Epub 2012 Aug 30.
Use of antifungal drugs in hematology.
Rev Bras Hematol Hemoter. 2012
Use of antifungal drugs in hematology.
Nucci M. Rev Bras Hematol Hemoter. 2012; 34(5):383-91.
A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis.
Eur J Clin Microbiol Infect Dis. 2013
A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis.
Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S, Kamei K, Miyazaki Y, Yoshinari T, Kartsonis NA, Niki Y. Eur J Clin Microbiol Infect Dis. 2013 Mar; 32(3):387-97. Epub 2012 Oct 3.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster